Protocol Ledger

NCT03473223 · Phase III · COMPLETED

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Interventional Phase III clinical trial protocol NCT03473223 sponsored by CSL Behring in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-03-21 Enrollment: 18,226 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03473223
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)18,226 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03473223
Protocol FieldVerified Registry Value
NCT IdentifierNCT03473223
Consolidated Lead SponsorCSL Behring
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment18,226 participants (ACTUAL)
Registered Start Date2018-03-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI